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ABSTRACT
Nuclear receptor peroxisome proliferator-activated recep-
tor-c (PPARc) is an essential transcription factor for adi-
pocyte differentiation. In mesenchymal stem cells, PPARc
has been assumed to play a negative role in osteoblastic dif-
ferentiation, by working in an adipogenesis dependent
manner, due to the reciprocal relationship between osteo-
blast and adipocyte differentiation. However, the direct
role of PPARc in osteoblast function is not fully under-
stood, due in part to inadequate model systems. Here, we
describe an adenoviral-mediated PPARc knockout system
in which suppression of PPARc in mesenchymal stem cells
enhanced osteoblast differentiation and inhibited adipogen-
esis in vitro. Consistent with this in vitro observation, lip-
oatrophic A-ZIP/F1 mice, which do not form adipocytes,
displayed a phenotype in which both cortical and trabecu-
lar bone was significantly increased compared with wild-
type mice. We next developed an inducible osteoblast-
targeted PPARc knockout (Osx Cre/flox- PPARc) mouse to
determine the direct role of PPARc in bone formation.
Data from both in vitro cultures of mesenchymal stem cells
and in vivo mCT analysis of bones suggest that suppression
of PPARc activity in osteoblasts significantly increased
osteoblast differentiation and trabecular number. Endoge-
nous PPARc in mesenchymal stem cells and osteoblasts
strongly inhibited Akt/mammalian target of rapamycin
(mTOR)/p70S6k activity and led to decreased osteoblastic
differentiation. Therefore, we conclude that PPARc modu-
lates osteoblast differentiation and bone formation through
both direct and indirect mechanisms. The direct mode, as
shown here, involves PPARc regulation of the mTOR
pathway, while the indirect pathway is dependent on the
regulation of adipogenesis. STEM CELLS 2013;31:2183–2192
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INTRODUCTION
Nuclear receptor peroxisome proliferator-activated receptor-c
(PPARc) is an essential transcription factor for adipocyte dif-
ferentiation. Evidence for this requirement is derived from
observations that embryonic stem cells (ESC) from mice lack-
ing PPARc are unable to differentiate into fat tissue [1] and
that over-expression of PPARc in fibroblasts initiates adipo-
genesis [2]. Expression of PPARc is activated by naturally
occurring fatty acids, peroxisome proliferators, and the thiazo-
lidinedione (TZD) class of antidiabetic agents [3]. The TZDs,
which function to lower blood glucose, have been widely
used for the treatment of type 2 diabetes mellitus. Unfortu-
nately, a significant side effect of this therapy is the potential
for bone loss and subsequent skeletal fractures in diabetic
patients [4]. This clinical consequence may be due to an
imbalance between osteogenesis and adipogenesis when
PPARc is overactivated in response to TZD [4]. However, the
specific role of PPARc in osteogenesis is not fully
understood.
A direct role for PPARc in bone formation has been diffi-
cult to determine because of the reciprocal regulation relation-
ship that is hypothesized to exist between osteoblast and
adipocyte differentiation of mesenchymal progenitor cells. For
example, age-related osteoporosis is most often accompanied
by an increase in bone marrow adipose tissue and it is
believed that fat increases when osteoblasts are decreasd
because progenitors form adipocytes instead of osteoblasts
[5]. In contrast, PPARc-deficient ES cells fail to differentiate
into adipocytes, but instead spontaneously differentiate into
osteoblasts [1]. In transgenic animal models, PPARc-
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insufficient mice exhibit high bone mass with increased osteo-
genesis and decreased adipogenesis [6]. Adipocytes also
directly modulate osteoblast function through paracrine effects
of secretory adipocytokines, such as adiponectin and leptin
[7–10]. Taken together, these data suggest that PPARc regu-
lates bone formation in an indirect manner, a reciprocal effect
of its primary modulation of adipogenesis and/or through adi-
pocytokines. However, functional PPARc is also expressed in
mouse and human osteoblasts [11–13], which suggests that
PPARc may play a direct role in regulating osteogenesis. One
recent study indicates that osteoblast-targeted over-expression
of PPARc significantly reduces bone mass in mice [14]. How-
ever, it has also been reported that over-expression of PPARc
induces trans-differentiation of osteoblasts to adipocytes [15].
The PPARc over-expression mouse model is therefore not
sufficient to completely understand the physiologic role of
PPARc in osteogenesis. Moreover, recent evidence indicates
that suppression of adipogenesis by inhibition of PPARc is
not able to increase osteogenesis either in vitro or in vivo
[16,17]. Therefore, it is essential to determine the extent to
which PPARc has a direct role in osteoblast function and
bone formation.
Because the molecular mechanisms by which PPARc
could regulate osteoblasts are not fully understood, we sought
to determine how PPARc might interact with a key metabolic
signaling pathway in bone. Mammalian target of rapamycin
(mTOR) is the catalytic subunit of two distinct signaling com-
plexes, mTOR complexes 1 and 2 (mTORC1 and mTORC2)
[18]. mTORC1 activates ribosomal S6 kinase (S6K) and inac-
tivates eukaryotic initiation factor 4E binding protein 1
(4EBP1) and thus stimulates protein synthesis, cell growth,
cell proliferation, and progression through the cell cycle. Pro-
motion of cell survival and cytoskeletal reorganization is also
enhanced when mTORC2 activates Akt and PKCa [19–21].
Recent work also supports an important role of mTOR in the
regulation of cell differentiation [22–25].
It is well known that the global protein translation level
in stem cells is lower than differentiated cells, whereas the
activation of protein translation in these stem cells can initiate
differentiation [22–25]. We, and others, recently demonstrated
that mTOR signaling plays an essential role in osteoblast dif-
ferentiation in vitro [26–30]. It is notable that rapamycin, an
inhibitor of mTOR, inhibits osteogenesis both in vitro and in
vivo [31]. Moreover, mTOR also plays an important role in
PPARc-mediated adipogenesis [32,33]. These data suggest a
potential for crosstalk between the mTOR and PPARc path-
ways, both of which are important for osteogenesis. In this
study, we used in vitro models and developed a new
osteoblast-specific PPARc knockout mouse to study the physi-
ologic role of endogenous PPARc in bone formation and
found that the mTOR pathway was directly involved in
PPARc-mediated modulation of osteogenesis and conclude




Bone marrow mesenchymal stem cells (BMSCs) were harvested
and cultured as described previously [34,35] with modifications.
Briefly, femora and tibiae were dissected free of surrounding soft
tissues. The aspirates were flushed with a-Modified Eagle’s
Medium (a-MEM; Invitrogen, Carlsbad, CA), and filtered through
a 40-mm cell strainer. The marrow content of 4–6 bones was
plated into a T75 culture flask in BMSC growth medium
comprised of a-MEM containing 10% fetal bovine serum (FBS),
100 U/mL penicillin, 100 mg/mL streptomycin sulfate (Gibco,
Grand Island, NY). Nonadherent cells were removed and adher-
ent BMSCs were cultured and expanded for further experiments.
Primary cells prior to passage four were used in the experiments.
It is generally believed that BMSCs are the common progenitors
for osteoblasts and adipocytes. As a primary cell type, BMSCs
may more likely reflect the nature of cells of the bone marrow, in
addition to their potential for clinical use when compared with
cells lines. However, BMSCs are a heterogeneous population.
Therefore, the well-defined bone marrow stromal cell line, ST2
[36], which has osteoblast/adipocyte bipotential, is an ideal cell
type for mechanistic studies on the reciprocal relationship
between osteoblast and adipocyte differentiation. Similarly, the
preosteoblast cell line MC3T3-E1 is an appropriate cell type to
study molecular mechanisms when the cells have been committed
to osteoblasts. ST2 and MC3T3-E1 cells were cultured in High
Glucose Dulbecco’s Modified Eagle Medium (HG-DMEM) con-
taining 10% FBS, 100U/mL penicillin, 100 mg/mL streptomycin
sulfate (Gibco, Grand Island, NY), and a-MEM containing 10%
FBS, 100U/mL penicillin, and 100 mg/mL streptomycin sulfate,
respectively.
PPARc was activated by 5 mg/mL Troglitazone (Trog, Cay-
man Chemical, Ann Arbor, MI), and the vehicle, dimethyl sulfox-
ide (DMSO, Sigma, St. Louis, MO.)-treated group was included
as the control. BMSCs from PPARc flox/flox mice were trans-
fected with adenovirus as described previously [9] with minor
modifications. The cells were plated at a density of 20,000 cells/
cm2 in T75 flasks. After 4 hours, virus was added at a multiplic-
ity of infection of 1,000 in 4 mL a-MEM with 0.5% FBS. The
virus-containing medium was removed and complete fresh
medium was added after 4-hour cell transduction. Adenovirus-
expressing cre recombinase (Ad-Cre) was harvested on February
19, 2009, and viral titer was 2.40E11 plaque forming unit (PFU)
per milliliter. Adenovirus CMVpLpA.dlE3 #1 (Ad-Blank) was
harvested on February 18, 2001, and viral titer was 1.30E11 PFU
per milliliter.
Gene Expression Analysis
Polymerase chain reaction (PCR) analysis to detect knockout of
PPARc by Ad-Cre was performed as described previously [37]
with modifications. Genomic DNA in the transfected BMSCs was
harvested using the DNeasy Blood and Tissue Kit (Qiagen, Ger-
mantow, MD). The primers for genotyping included one forward
primer 2F: CTC CAA TGT TCT CAA ACT TAC and two
reverse primers 1R: GAT GAG TCA TGT AAG TTG ACC and
H5: GTA TTC TAT GGC TTC CAG TGC. Primer pair 2F/1R
was designed to amplify the intact PPARc gene and the amplified
length was 285 bp. Primer pair 2F/H5 was used to detect the
deleted gene and the amplified length was 450 bp. Thermal
cycling conditions were as follows: 95C, 5 minutes, 40 cycles at
(95C, 30 seconds, 55C, 30 seconds, 72C, 45 seconds), 72C, 5
minutes and 4C. A 2% agarose–TAE gel electrophoresis fol-
lowed by ethidium bromide staining was used to detect bands.
For the osteogenic and adipogenic gene expressions of the
Ad-Cre BMSCs, the total RNA was isolated using the RNeasyMi-
cro Kit (Qiagen, Germantow, MD). RNA concentration was
determined at 260 nm and an equivalent amount of RNA sample
(2 mg) was processed to generate cDNA using the High Capacity
cDNA Reverse Transcript kit (Applied Biosystems, Forster City,
CA). Quantitative PCR was performed by the SYBR Green PCR
method using the ABI PRISM 7,500 sequence detection system
(Applied Biosystems, Carlsbad, CA, USA). The housekeeping
gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was
used for normalization, GAPDH_F: TGA AGC AGG CAT CTG
AGG G; GAPDH_R: CGA AGG TGG AAG AGT GGG AG. Pri-
mers for osteocalcin (OCN) and fatty acid binding protein 4
(FABP4) were: OCN_F: CAA GCA GGG TTA AGC TCA CA;
OCN_R: GGT AGT GAA CAG ACT CCG GC [9]; FABP4_-
F:AAT GTG TGA TGC CTT TGT GG; FABP4_R: CAC TTT
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CCT TGT GGC AAA GC. Gene expressions in ST2 and
MC3T3-E1 cells were performed with Taqman gene expression
assays (Applied Biosystems, Forster City, CA). The genes ana-
lyzed were: GAPDH (Mm99999915), Runx2 (Mm00501584),
OCN (Mm-03413826), and PPARc (Mm01184322) (Applied Bio-
systems, Forster City, CA).
In Vitro Mineralization Assays
The mineralization assay used for primary BMSCs was described
previously [9]. Briefly, cells were plated in 12-well or 24-well
plates at 20,000 cells/cm2. Plated cells were allowed to grow to
confluence in growth medium. After reaching confluence, cells
were cultured in osteogenic medium (BMSC Growth Medium-
1 100 nM dexamethasone, 10 mM b-glycerophosphate, and 50
mM ascorbic acid 2-phosphate (all from Sigma, St. Louis, MO.))
for up to 14 days. The same protocol was used for ST2 and
MC3T3-E1 cells except the osteogenic medium did not contain
dexamethasone. Subsequently, cells were fixed with cold 70%
ethanol for 1 hour, rinsed with water, stained for 10 minutes in
40 mM Alizarin red S (pH 4.2), and washed extensively with
water. After imaging, the dye was eluted with 10% w/v hexade-
cylpyridinium chloride monohydrate (Wako, Chemical, Osaka,
Japan) in 10 mM sodium phosphate pH 7.0 and concentration
was determined by absorbance measurement at 562 nm. The
results were normalized to total genomic DNA content.
In Vitro Adipogenic Differentiation Assays
The adipogenic differentiation assay was performed as described
previously [9]. Briefly cells were plated at 40,000 cells per square
centimeter and grown to confluence in HG-DMEM growth
medium (HG-DMEM containing 10% FBS, 100U/mL penicillin,
and 100 mg/mL streptomycin sulfate). Cells were induced with
adipogenic medium (HG-DMEM growth medium1 50 mM isobu-
tylmethylxanthine (Sigma, St. Louis, MO.), 1 mM dexamethasone
(Sigma, St. Louis, MO.), 167 nM insulin (Sigma, St. Louis,
MO.), and 5 mg/mL Troglitazone (Cayman Chemical, Ann Arbor,
MI)) for 2 days. Adipogenic maintenance medium (HG-DMEM
Growth Medium1 167 nM insulin) was then added for another 2
days. This process of induction medium followed by maintenance
media was repeated three times. Cells were then fixed in zinc-
buffered formalin (Z-fix, Anatech LTD, Battle Creek, MI) for
half hour and stained with oil red O solution (Sigma, St. Louis,
MO.). Dye was eluted in 100% isopropanol and quantified at 500
nm. The results were normalized to total genomic DNA.
Genetically Modified Mice
Animal experiments were approved by the institutional animal care
and use committee. PPARc-floxed mice [19] were crossed with tetra-
cycline regulatable osterix-Cre mice [38] purchased from Jackson
Laboratories (B6.Cg-Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/J; Stock Num-
ber: 006361). Mice were maintained on Doxycycline feed (Harlan
Item #: TD.01306; Rodent Diet (2018, 625 Doxycycline) throughout
the entire process of crossing the two lines to achieve homozygozity
of the floxed PPARc allele. Mice that were Osx-Cre positive/PPARc
f/f (experimental) or that were Osx-Cre negative/PPARc f/f or (con-
trol) were removed from the Doxycycline feed at weaning (3
weeks) and harvested at 6 months of age. For the in vitro experi-
ments, BMSCs from the experimental and control mice were isolated,
cultured and differentiated using the same methods as aforementioned.
To further investigate the role of adipogenesis in bone formation in
an in vivo context, we tested our hypothesis in A-ZIP/F1 fatless mice
that do not form adipocytes due to the expression of a dominant-
negative form of C/EBP under the FABP4 promoter [39]. AZip-F1
mice were provided by Dr. Chuck Vinson and harvested as indicated
for evaluation of bone geometric parameters using microCT.
mCT 3D Reconstruction and Bone Morphometry
Femurs were fixed for 2 days with Z-fix (Anatech LTD, Battle
Creek, MI), then moved to 70% ethanol, and scanned at a voxel
size of 18 mm using a mCT scanner (GE Healthcare Pre-Clinical
Imaging, London, ON). Micro View software (GE Healthcare
Pre-Clinical Imaging) was used to generate a three-dimensional
reconstruction from the set of scans. Assessment of bone micro-
structure was carried out according to the guidelines developed
by Bouxsein et al. [40]. The region selected for cortical bone
parameters was defined to be the central portion between the
proximal and distal ends of the femur. Trabecular bone parame-
ters were measured by analyzing the metaphyseal region adjacent
to growth plate. User-defined contours were drawn every five
images and interpolated for all images in between. The thresholds
for cortical and trabecular bone were set to 2,000 and 1,200,
respectively.
Western Blot Analysis
Primary BMSCs transfected with Ad-Cre/Ad-Blank after 3 days were
harvested for Western Blot analysis. ST2 and MC3T3-E1 cells were
treated with 50 mM bisphenol A diglycidyl ether (BADGE, Sigma,
St. Louis, MO.) for 24 hours and harvested as well for Western Blot
analysis as described previously [26]. Briefly, whole cell lysates were
separated on 10% SDS–polyacrylamide gel and transferred to PVDF
membrane. The membranes were incubated with 5% milk for 1 hour
and incubated with primary antibodies overnight at 4C. Primary anti-
bodies used were as follows: polyclonal anti-phospho-AKT (1:500;
Cell Signaling, Danvers, MA), polyclonal anti-AKT (1:1,000; Cell
Signaling), polyclonal anti-phospho-p70S6K (1:500; Cell Signaling),
polyclonal anti-p70S6K (1:1,000; Cell Signaling), polyclonal anti-
PPARc (1:1,000; Santa Cruz Biotechnology, Santa Cruz, CA), poly-
clonal anti-RUNX2 (1:1,000; Santa Cruz), and polyclonal anti-
Osteocalcin (1:1,000; Millipore). Blots were incubated with
peroxidase-coupled secondary antibodies (Promega, Madison, WI) for
1 hour, and protein expression was detected with SuperSignal West
Pico Chemiluminescent Substrate (Thermo Scientific, Rockford, IL).
Membranes were reprobed with polyclonal anti-b-actin antibody
(1:1,000; Cell Signaling) to control for equal loading.
Statistical Analysis and Image Editing
To determine statistical significance of observed differences
between the study groups, a two-tailed homoscedastic t-test was
applied. A value of p< .05 was considered to be statistically sig-
nificant while 0.05<p< .10 was considered to represent a non-
significant, but clear trend in cell or tissue response. Values are
reported as the mean6SD. Brightness and contrast were adjusted
equally across all images for improved visibility.
RESULTS
Knockout of PPARc in BMSCs Increases
Osteogenesis and Inhibits Adipogenesis
Primary BMSCs were isolated from PPARc flox/flox mice to
study the effects of PPARc gene knockout on adipogenesis
and osteogenesis. PCR-based genotyping assays demonstrated
robust LoxP recombination indicating loss of PPARc at the
gene level (450bp band) in BMSCs after Ad-Cre delivery,
while no band was detected in the control group (Ad-Blank)
(Fig. 1A). It was noted that residual intact PPARc (285 bp
band) remained in the deleted group. Consistent with the
essential role of PPARc in adipogenesis, the adipogenic dif-
ferentiation of BMSCs was largely inhibited by in vitro
PPARc gene knockout. When PPARc expression was abro-
gated, oil red O staining and FABP4 gene expression was
diminished (Fig. 1B). In contrast, PPARc knockout led to sig-
nificantly increased mineralization and OCN gene expression
in BMSCs (Fig. 1C). This in vitro adenoviral-mediated
PPARc knockout system therefore demonstrated that
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suppression of PPARc enhanced osteogenesis and reduced
adipogenesis.
Osteogenesis Is Modulated by PPARc-Mediated Adi-
pogenesis In Vitro and In Vivo
After a 2-week culture period in osteogenic medium, ST2 cells
were strongly positive for Alizarin red S staining (Fig. 2A).
This finding is in contrast to the effects observed when PPARc
was activated. Mineralization of ST2 cells was inhibited when
PPARc was activated by troglitazone, a PPARc ligand that
supports PPAR activation. Accordingly, troglitazone-treated
ST2 cells switched to an adipogenic phenotype with oil red O-
positive lipid droplets accumulating in cultured cells (Fig.
2A), suggestings that osteogenesis was negatively modulated
by PPARc-induced adipogenesis.
Micro-CT data from A-ZIP/F1 mouse long bones demon-
strated a clear trend (0.05<p< .10) in which cortical bone was
increased in A-ZIP/F1 relative to wild-type mice. These param-
eters included mean cortical thickness, bone mineral content
(BMC) and bone mineral density (BMD). In line with this trend,
the marrow area in A-ZIP/F1 bones was significantly lower than
in wild-type mice (Fig. 2B). Compared with cortical bone, the
effects of adipogenic deficiency were more profound for trabec-
ular bone formation in A-ZIP/F1 mice. The bone mCT values,
including bone surface/bone volume (BS/BV) and trabecular
spacing (Tb.Sp.), were significantly decreased, while trabecular
number (Tb.N) was significantly increased in A-ZIP/F1 mice.
The bone/tissue volume (BV/TV) ratio also indicated a higher
trend (0.05<p< .10) in A-ZIP/F1 mice (Fig. 2C). Therefore,
both our in vitro and in vivo data indicated that PPARc-
mediated adipogenesis negatively regulated bone formation.
Osteoblast-Targeted PPARc Suppression Increased
Osteogenesis In Vitro
Based on the opposing effects on mineralization when PPARc
was either knocked out or activated, we hypothesized that the
inhibitory effects of PPAR activation on bone formation were
due, in part, to its proadipogeneic function. Therefore, to
determine if PPARc had a direct role in osteogenesis that was
independent on adipogenesis, BMSCs from osteoblast-targeted
PPARc knockout mice were isolated and their capacity for
osteogenic differentiation was examined. Compared with the
BMSCs from WT mice, BMSCs from osteoblast-targeted
PPARc knockout mice demonstrated much higher mineraliza-
tion after 2 weeks in culture in osteogenic differentiation
medium (Fig. 3A). The finding that mineralization was
enhanced when PPARc was blocked was corroborated in pre-
osteoblastic MC3T3-E1 cells when they were treated with
BADGE, an effective antagonist of PPARc (Fig. 3B). The
effects of PPARc inhibition on osteoblast-related gene expres-
sion in ST2 and MC3T3-E1 were tested after 24 hours
BADGE treatment. Osteocalcin gene expression was enhanced
by BADGE, while no significant difference was noticed for
Runx2 expression in either cell type. Interestingly, expression
of PPARc was also increased by BADGE treatment (Fig. 3C).
Taken together, these data suggest that PPARc in osteoblasts
or preosteoblastic cells is able to modulate osteogenic differen-
tiation through a direct manner in vitro.
Figure 1. Knockout of PPARc in bone marrow mesenchymal stem cells (BMSCs) increases osteogenesis and inhibits adipogenesis. (A): Poly-
merase chain reaction-based genotyping. The deleted bands (450 bp) were detected only in the AdCRE group (CRE), while the intact bands (285
bp) were detected in both control (CON) and CRE groups. (B): PPARc is essential for adipogenesis in BMSCs. Oil red O staining and FABP4
gene expression were diminished when PPARc expression was abrogated by Ad-Cre (n5 3). (C): PPARc knockout increases osteogenesis.
PPARc knockout led to significantly increased mineralization and OCN gene expression in BMSCs (n5 3). Data are expressed as means6SD.
Scale bar5 50 mm. Abbreviations: CON, control; CRE, AdCRE group; FABP4, fatty acid binding protein 4.
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Osteoblast-Targeted PPARc Knockout Increases
Trabecular Number in Adult Mice
To directly assess bone mass when PPARc is not expressed in
osteoblasts, an inducible osteoblast-targeted PPARc knockout
mouse model was developed. Femurs from control and
experimental groups were harvested and analyzed at 6 months
of age. Quantitative data from mCT analyses demonstrated
that PPARc deletion in osteoblasts had little effect on cortical
bone as they demonstrated similar mean thickness and mar-
row area (Fig. 4A, 4B). In contrast, the structure of trabecular
Figure 2. Osteogenesis is modulated by PPARc-mediated adipogenesis in vitro and in vivo. (A): Osteogenic differentiation of ST2 cells is inhibited
by PPARc activation. After a 2-week culture in osteogenic medium, ST2 cells were strongly positive for alizarin red S staining. Mineralization of ST2
cells was inhibited when PPARc was activated by troglitazone. Accordingly, troglitazone-treated ST2 cells switched to an adipogenic phenotype with
oil red O-positive lipid droplets in cultured cells (n5 4). Scale bar5 100 mm. (B): Cortical bone formation is increased in A-ZIP/F1 fatless mice.
Micro-CT data, including mean cortical thickness, bone mineral content (BMC), and bone mineral density (BMD), demonstrated a clear trend
(0.05<p< .10) that cortical bone was increased in A-ZIP/F1 (n5 5) relative to wild-type (n5 6) mice. The marrow area in A-ZIP/F1 bones was sig-
nificantly lower than in wild-type mice. (C): Trabecular bone formation is increased in A-ZIP/F1 fatless mice. The bone mCT values, including bone
surface/bone volume (BS/BV) and trabecular spacing (Tb.Sp.), were significantly decreased, while trabecular number (Tb.N) was significantly
increased in A-ZIP/F1 mice. The bone/tissue volume (BV/TV) ratio also indicated a higher trend (0.05<p< .10) in A-ZIP/F1 mice (n5 5) compared
with wild-type mice (n5 6). Data are expressed as means 6SD. Abbreviations: BMC, bone mineral content; BMD, bone mineral density; BS, bone
surface; BV, bone volume; DMSO, dimethyl sulfoxide; Tb.N., Trabecular number; Tb.Sp., trabecular spacing; TV, tissue volume; WT, wild type.
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bone was significantly altered by deletion of PPARc in osteo-
blasts (Fig. 4A, 4C). Among the trabecular analyses, trabecu-
lar number (Tb.N.) was significantly increased and trabecular
spacing (Tb.Sp) was significantly decreased in PPARc KO
mice. The bone volume fraction (BV/TV) also indicated a
clear trend towards increasing BV/TV (0.05<p< .10) in KO
mice (Fig. 4A, 4C). Therefore, conditional deletion of PPARc
in osteoblasts significantly increased trabecular number, while
it had limited effects on cortical bone. These in vivo data also
suggest that PPARc plays a direct role in osteoblastogenesis
in addition to its primary role in adipogenesis.
Suppression of Endogenous PPARc Increases mTOR
Signaling and Osteogenesis
The in vitro deletion of PPARc in BMSCs dramatically ele-
vated phosphorylation of p70S6K (p-p70S6K), which is the
primary down-stream effector of mTOR signaling (Fig. 5A).
Consistent with the increase in p-p70S6K, phosphorylation of
AKT (p-AKT), which is one of the up-steam activators for
mTOR signaling, was also enhanced when Ad-Cre was used
to knockdown PPARc (Fig. 5A). In complementary studies,
the level of p-p70S6K was significantly increased in MC3T3-
E1 and ST2 cells after 24-hour treatment with BADGE. It
was noted that the basal level of p-p70S6K in ST2 cells was
much lower than in 3T3-E1 cells. The levels of p-AKT were
also increased in both cell types after BADGE-induced
PPARc suppression. In addition, treatment with BADGE
resulted in elevated levels of Runx2 and/or OCN in ST2 and
MC3T3-E1 cells (Fig. 5B). Consistent with the data support-
ing the hypothesis that PPARc influences osteoblast differen-
tiation by inhibiting mTOR signaling, mineralization of
MC3T3-E1 cells exposed to BADGE was severely inhibited
by rapamycin treatment (Fig. 5C), suggesting that rapamycin
can rescue the loss of PPARc activity. These data indicate
that endogenous PPARc in osteoblasts inhibited the activity
of mTOR signaling, which is essential for osteogenesis. Con-
sistent with the in vitro data, the levels of phosphorylation of
p70S6K (p-p70S6K, red staining) in osteoblasts and osteo-
cytes were clearly increased in the PPARc KO mice (Support-
ing Information Fig. 1). Therefore, our data strongly suggest
that the negative effects of PPARc on osteogenesis are par-
tially mediated through inhibition of mTOR signaling.
DISCUSSION
In the current study, PPARc was specifically deleted in vitro
and in osteoblasts in adult mice. Collectively, the data indi-
cated that PPARc negatively regulates osteoblast differentia-
tion and bone formation. Additionally, it was determined that
PPARc inhibits mTOR signaling because either disruption of
PPARc expression, or treatment with the PPARc inhibitor
BADGE increases mTOR signaling and increases osteoblast
differentiation.
In addition to adipogenesis, PPARc regulates a variety of
physiologic processes including lipid metabolism, insulin sen-
sitivity, inflammation, angiogenesis and osteoclastogenesis
[3,41–43]. Among these PPARc-mediated physiologic proc-
esses, adipogenesis, inflammation, angiogenesis and osteoclas-
togenesis are known to be involved in bone homeostasis
[3,41,44–46]. However, due to overlapping signaling in these
complex biologic functions, it is difficult to distinguish the
direct role and mechanism of action for PPARc in osteogene-
sis [6,47,48]. Most of the available evidence suggests that the
Figure 3. Osteoblast-targeted PPARc suppression increased osteogenesis in vitro. (A): Osteoblast-targeted PPARc knockout increases minerali-
zation. Compared with the bone marrow mesenchymal stem cells (BMSCs) from WT mice, BMSCs from osteoblast-targeted PPARc knockout
mice demonstrated much higher mineralization after 2 week-culture in osteogenic differentiation medium (n5 3). Scale bar5 100 mm. (B): Min-
eralization is increased by PPARc antagonist. The mineralization in MC3T3-E1 cells was enhanced when PPARc was blocked by bisphenol A
diglycidyl ether (BADGE) (n5 3). (C, D) Gene expression in BADGE-treated ST2 and MC3T3-E1 cells. The effects of PPARc inhibition on
osteoblast-related gene expression in ST2 and MC3T3-E1 were tested after 24 hours BADGE treatment. Osteocalcin (OCN) gene expression was
enhanced by BADGE, while no significant difference was noticed for Runx2 expression in either cell type. Expression of PPARc was also
slightly increased by BADGE treatment (n5 3). Data are expressed as means6 SD. Abbreviations: BADGE, bisphenol A diglycidyl ether; CON,
control, KO, knockout; WT, wild type.
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negative effects of PPARc on bone formation are through an
adipogenesis-dependent mechanism. This conclusion may be
explained by the reciprocal relationship between osteoblasts
and adipocytes, which are both derived from mesenchymal
stem cells [49]. Furthermore, TZD treatment is known to
stimulate the secretion of adiponectin and tumor necrosis fac-
tor alpha (TNF-a) from fat tissue and thereby induce bone
loss [50,51]. However, the notion of a reciprocal relationship
between adipogenesis and osteogenesis in the marrow is chal-
lenged by emerging data that suggest that the inhibition of
adipogenesis is not always accompanied by increased osteo-
genesis [16,17]. For example, systemic treatment with
BADGE, a PPARc antagonist, effectively blocks type I
diabetes-induced hyperlipidemia and bone marrow adiposity.
However, BADGE treatment is not able to block type I
diabetes-induced bone loss [16]. In line with this in vivo find-
ing, BADGE and GW9662, two antagonists of PPARc, as
well as lentivirus-mediated knockdown of PPARc, inhibit adi-
pocyte differentiation from MSC without significantly affect-
ing osteogenesis [17].
Because of conflicting evidence linking adipogenesis and
osteogenesis, we sought to directly study the contribution of
PPARc in osteogenic differentiation. We isolated BMSCs
from PPARc flox/flox mice and administered Ad-Cre to
knockout PPARc in vitro. Before cell harvest and addition of
Ad-Cre, the flox/flox mice have the same phenotype as wild-
type mice. Use of this system eliminates the potential for
systemic regulation of precursor cells that may otherwise be
present in traditional phenotypically altered PPARc knockout
animals. Moreover, compared with the chemical antagonists
(BADGE and GW9662), the Ad-Cre assay has minimal side
effects because it is designed to specifically target the PPARc
gene. The in vitro data support the finding that PPARc is
essential for adipogenesis and that osteogenic differentiation
is enhanced when endogenous PPARc is deleted in BMSCs.
To further determine the effects of adipogenesis on bone
formation, we used the A-ZIP/F1 mouse model. Adipogenesis
in these mice is largely blocked due to the expression of a
dominant-negative form of C/EBP under the adipocyte fatty-
acid-binding protein four (FABP4) promoter, while the
expression of PPARc is not affected [39]. The mCT data dem-
onstrated that both cortical and trabecular bone were signifi-
cantly increased in these adipoatrophic mice. In contrast,
when adipogenesis was induced by PPARc activation, osteo-
genesis was blocked in ST2 cells. It has also been reported
that inhibition of adipogenesis in whole animals has profound
effects in addition to regulation of osteogenesis. For example,
in lipoatrophic A-ZIP/F1 ‘fatless’ mice, and in mice treated
with BADGE, marrow engraftment after irradiation is acceler-
ated relative to wild-type or untreated mice [52]. This finding
suggests that suppression of adipogenesis may not only
enhance osteogenesis but may increase hematopoiesis as well.
In addition to the indirect adipogenesis-mediated effects
of PPARc on osteogenesis, several lines of study from in vitro
Figure 4. Osteoblast-Targeted PPARc knockout increases trabecular number in adult mice. (A): 3D reconstructed mCT images of cortical, tra-
becular bone and the region of interest (ROI) for cortical and trabecular bone analyses in Control (n5 6) and PPARc KO group (n5 5). Scale
bar (left panel5 250 mm; Scale bar (right panel)5 1 mm. (B): mCT analysis of cortical bone. PPARc deletion in osteoblasts had little effect on
cortical bone as they demonstrated similar mean thickness and marrow area. (C): mCT analysis of trabecular bone. The structure of trabecular
bone was significantly altered by deletion of PPARc in osteoblasts. Trabecular number (Tb.N.) was significantly increased and trabecular spacing
(Tb.Sp) was significantly decreased in PPARc KO mice. The bone volume fraction (BV/TV) also indicated a clear trend of increasing BV/TV
(0.05<p< .10) in KO mice. Data are expressed as means6 SD. Abbreviations: BMD, bone mineral density; BV, bone volume; KO, knockout;
Tb.N., Trabecular number; Tb.Sp., trabecular spacing.
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systems also suggest that PPARc may have a direct effect on
osteoblast differentiation. It has been reported by several groups
that functional PPARc is expressed in osteoblasts [11–13].
Moreover, the pro-adipogenic and anti-osteoblastic PPARc
activities can be separately activated by different ligands [53].
Further studies indicate that PPARc pro-adipogenic activity
involves binding to peroxisome proliferator-activated receptor-
response element (PPRE) in gene regulatory regions while its
anti-osteoblastic activity is PPRE-independent [54]. To study
the role of PPARc in osteoblast function, we specifically deleted
PPARc in osteoblasts by using the Cre/loxP system. BMSCs
from the PPARc KO (Osx Cre/flox- PPARc) mice demonstrated
a higher mineralization capacity compared with the cells from
WT mice. Consistent with the in vitro results, the mCT analyses
revealed that several trabecular bone parameters were signifi-
cantly increased in PPARc KO mice compared with the WT
mice. Our findings are supported by a recent report that in vivo
over-expression of PPARc specifically in osteoblasts under the
control of a 2.3-kb procollagen type 1 promoter negatively reg-
ulates bone mass in male mice [14]. It is noted that the over-
expression model may result in more unexpected changes to the
mice compared with our conditional KO model. Indeed, they
disclose that osteoclastogenesis is significantly inhibited in mice
overexpressing PPARc [14]. However, it is known that PPARc
is a pro-osteoclastogeneic regulator in vitro and in vivo [45].
Moreover, over-expression of PPARc in osteoblasts unexpect-
edly increases adipogenesis of BMSCs in vitro although no sig-
nificant difference in vivo was reported [14]. These drawbacks
from the over-expression strategy are mitigated in the tetracy-
cline (tet)-inducible Cre/loxP system (Tet-Off) used in our
experiments. Tetracycline has been widely used in bone histo-
morphometry to label new bone formation [55] and to regulate
the Cre recombinase gene in knockout mice [56]. Doxycycline,
a member of the tetracycline family, was used in our control
group to maintain normal PPARc functions by inhibiting the
expression of Cre recombinase. However, it has been reported
that tetracyclines are able to increase bone formation by both
increasing osteoblast activity and inhibiting osteoclast function
[57]. Therefore, the difference in bone formation due to PPARc
knockout may be masked by doxycycline treatment, which is
one of the possible reasons that BVF (p5 0.07) did not achieve
statistical significance in the KO group relative to the control
group, because our control group was provided doxycycline to
repress Cre activity.
Our data indicate that PPARc is able to regulate osteo-
blast differentiation and bone formation through both indirect
and direct mechanisms. The indirect pathway is related to
reciprocal differentiation as has been discussed previously.
Figure 5. Suppression of endogenous PPARc increases mTOR sig-
naling and osteogenesis. (A): Deletion of PPARc in bone marrow
mesenchymal stem cells (BMSCs) dramatically increases mTOR sig-
naling. Deletion of PPARc in BMSCs dramatically elevated the phos-
phorylation of p70S6K (p-p70S6K) and phosphorylation of AKT (p-
AKT). (B): Suppression of endogenous PPARc by bisphenol A digly-
cidyl ether (BADGE) dramatically increases mTOR signaling in
MC3T3-E1 and ST2 cells. The levels of p-AKT and p-p70S6K were
increased in both cell types after BADGE-induced PPARc suppres-
sion. BADGE-treatment resulted in the elevated levels of Runx2 and/
or OCN in ST2 and MC3T3-E1 cells. (C): Rapamycin inhibits miner-
alization in osteoblasts. The BADGE-enhanced mineralization in
MC3T3-E1 cells was severely inhibited by rapamycin-treatment
(n5 3). Data are expressed as means6 SD. Abbreviations: BADGE,
bisphenol A diglycidyl ether; CON, contol; CRE, AdCRE group;
mBMSC, bone marrow mesenchymal stem cell.
Figure 6. PPARc modulates bone formation through direct and indi-
rect mechanisms. The indirect pathway is dependent on adipogenesis,
which includes not only the role of PPARc in the allocation of stem cells,
but also the potential negative regulation derived from adipocytes. The
direct mechanism is independent on adipogenesis. The endogenous
PPARc in osteoblasts strongly inhibits the mTOR activity, thus inhibiting
Runx2/Osteocalcin mediated osteoblastic differentiation. Abbreviations:
MSC, mesenchymal stem cell; mTOR, mammalian target of rapamycin.
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The direct regulation of osteogenesis, however, is not com-
pletely defined. Our recent work indicates that mTOR is
directly involved in odontoblast and osteoblast differentiation
[26,27]. The contribution of mTOR to bone formation is fur-
ther confirmed by a recent study in which significantly less
bone formation and a lower trabecular bone mass was
observed in rapamycin-treated C57BL/6 mice compared with
the vehicle-treated controls [31]. It is intriguing that in the
current study we demonstrated that the Akt/mTOR/p70S6K
pathway was activated after knockout of PPARc in BMSCs,
or by a PPARc antagonist in osteoblasts. Accordingly, osteo-
blastic markers were increased by the suppression of PPARc
activity. Moreover, osteoblastic differentiation following the
suppression of PPARc was blocked by rapamycin. Our data
are consistent with the previous finding that rapamycin inhib-
its osteoblast differentiation, while over-expression of p70S6K
significantly increases levels of Runx2 protein and Runx2
activity [29]. These results clearly indicate that the mTOR
pathway is essential for osteoblast differentiation and that it is
largely inhibited by endogenous PPARc in osteoblasts.
SUMMARY
In summary, our data demonstrate that PPARc modulates
bone formation through bimodal mechanisms (Fig. 6). The
indirect pathway is dependent on adipogenesis, which
includes not only the role of PPARc in the commitment of
stem cells, but also the potential for negative regulation by
adjacent mature adipocytes. The direct mechanism is inde-
pendent of adipogenesis. The direct suppression of PPARc in
osteoblasts significantly increases osteoblast differentiation
and trabecular bone formation which is demonstrated in the
Osx-PPARc knockout mouse model. We further demonstrate
that endogenous PPARc in osteoblasts strongly inhibits
mTOR activity, thus inhibiting osteoblastic differentiation.
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